Internal Medicine

How providers can stop the spread of dangerous information during the COVID-19 pandemic.

Individuals are encouraged to continuing donating blood despite the COVID-19 pandemic.

New findings show the addition of easily identified circulating proteins can provide a more accurate risk assessment.

Results of the 5-year Protocol T extension study are offering insight into the differences in real-world treatment and study protocol with anti-VEGF treatments.

There is a growing understanding that obesity and non-alcoholic fatty liver disease are related.

Currently, guidelines call for liver biopsies to diagnose NASH disease in patients.

Independent evaluations found NDMA levels increase over time and when stored in temperatures above room temperature.

The findings can lead to more education on the risk of thyroid immune-related adverse event.

An analysis shows that patients find desiccated thyroid extract to be more effective and improve patient outcomes better than other therapies.

How new DAPA-HF findings continue to build the SGLT2 inhibitors' cardiovascular portfolio.

African American and Hispanic patients use devices for type 1 diabetes less than Caucasian patients.

New data from ENDO 2020 suggests the presence of erectile dysfunction and sexual symptoms was linked to increased risk of death.

Treating thyrotropin changes associated with aging adaptation could adversely alter key homeostatic compensations.

Patients with fractures closer to the center of the body had a 1.5- to four-fold greater risk of death over 2 years of follow-up.

Patients of both sexes and differing levels of LVEF reported similar reductions in NT-proBNP when treated with the combination therapy, versus lone valsartan.

An interventional cardiologist shares perspective on what the new two-year TAVR findings mean for him and colleagues.

New secondary analsysis from the large-scale heart failure trial shows continued benefit of the SGLT2 inhibitor.

Results of the CARAVAGGIO trial found oral apixaban was noninferior to subcutaneous dalteparin for preventing cancer-associated VTE without increasing a patient’s risk for major bleeding.

New PRONOMOS data shows patients receiving lower limb surgery benefit significant from the oral anticoagulant—without increased risk of bleeding.

New trial data shows symptomatic patients with aortic stenosis reported noninferiority in rehospitalization and deaths with the lesser invasive option compared to surgery.

A heart failure and transplant cardiologist assesses the new study findings.

Discussing the impact of rivaroxaban 2.5 mg BID plus aspirin in diabetics versus nondiabetics from the COMPASS trial with Deepak Bhatt, MD.

Pooled pivotal phase 3 trial data from the ORION program shows the first-in-class therapy's significant benefit and tolerability versus placebo.

A board member of the college highlights 4 highly anticipated trials coming out of ACC 2020.

Marc Bonaca, MD, discusses the results of the VOYAGER-PAD trial in a special edition ACC House Call with HCPLive.